Evidence from the IMvigor210 clinical trial further supports this observation: patients who responded to therapy typically exhibited T cell–inflamed tumor phenotypes, marked by high PD-L1 expression on immune cells (IC2/3) (49). The gene discussed is CD274; the disease is neoplasm.